Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial

Abstract

Docetaxel-containing regimens are widely used as adjuvant treatment of early breast cancer, and the dose 100 mg/m² is often selected as the starting dose. Yet the optimal starting dose is unknown, since different docetaxel doses have never been compared in a randomised trial in the adjuvant setting. In metastatic breast cancer, three doses of docetaxel (60, 75 or 100 mg/m²) have been compared in one randomised phase III study. More tumour responses but no significant improvement in the time to disease progression or overall survival were achieved with the highest dose in the intention-to-treat population [1].